文献速递皮肤肿瘤

器官移植后皮肤癌风险的长期变化:一项全国性队列研究

Long-term Change in the Risk of Skin Cancer After Organ Transplantation: A Population-Based Nationwide Cohort Study.
PubMed 文献 · JAMA Dermatol · 2017-01-01

该研究基于挪威1968至2012年8026例实体器官移植受者的全国性前瞻队列,链接国家癌症登记数据,分析移植后皮肤鳞状细胞癌(SCC)、黑色素瘤和卡波西肉瘤的标准化发病比(SIR)。结果显示SCC总体SIR为51.9,但自1980年代中期以来SCC风险显著下降,调整后1998-2012年各时段相对SIR降至0.31-0.44。

要点

  • 器官移植受者SCC风险仍远高于一般人群,总体SIR为51.9。
  • 1983-1987年移植者SCC的SIR最高达102.7,随后显著下降。
  • 1998年后移植者调整后SIR降至0.31-0.44,提示风险减半以上。

核心结论

  • 挪威器官移植后SCC风险自1980年代中期以来显著下降,但仍远高于一般人群。

研究设计与样本

  • 基于挪威全国8026例肾脏、心脏、肺或肝脏移植受者的前瞻性队列研究,移植时间为1968至2012年,数据链接国家癌症登记。

主要发现

  • SCC、黑色素瘤和卡波西肉瘤的总体SIR分别为51.9(95% CI 48.4-55.5)、2.4(95% CI 1.9-3.0)和54.9(95% CI 27.4-98.2)。
  • 1983-1987年移植者SCC未调整SIR为102.7(95% CI 85.8-122.1),2003-2007年移植者降至21.6(95% CI 16.8-27.0)。
  • 调整随访时间、背景人群风险、年龄、移植器官和性别后,SCC的SIR在1983-1987年移植者中达峰,1998-2002、2003-2007和2008-2012年移植者的相对SIR分别为0.42(95% CI 0.32-0.55)、0.31(95% CI 0.22-0.42)和0.44(95% CI 0.30-0.66)。

临床怎么用

  • 器官移植受者仍需长期皮肤监测,尤其针对SCC。
  • 临床可关注免疫抑制方案的个体化调整以降低皮肤癌风险。
  • 移植科与皮肤科应协作进行移植后皮肤癌筛查与随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The high risk of skin cancer after organ transplantation is a major clinical challenge and well documented, but reports on temporal trends in the risk of posttransplant cutaneous squamous cell carcinoma (SCC) are few and appear contradictory. OBJECTIVE: To study temporal trends for the risk of skin cancer, particularly SCC, after organ transplantation. DESIGN, SETTING, AND PARTICIPANTS: Population-based, nationwide, prospective cohort study of 8026 patients receiving a kidney, heart, lung, or liver transplant in Norway from 1968 through 2012 using patient data linked to a national cancer registry. The study was conducted in a large organ transplantation center that serves the entire Norwegian population of approximately 5.2 million. EXPOSURES: Receiving a solid organ transplant owing to late-stage organ failure, followed by long-term immunosuppressive treatment according to graft-specific treatment protocols. MAIN OUTCOMES AND MEASURES: Occurrence of first posttransplant SCC, melanoma, or Kaposi sarcoma of the skin. Risk of skin cancer was analyzed using standardized incidence ratios (SIRs) and, for SCC, multivariable Poisson regression analysis of SIR ratios, adjusting for 5-year time period of transplantation, different follow-up time, age, sex, and type of organ. RESULTS: The study cohort included 8026 organ transplant recipients, 5224 men (65.1%), with a mean age at transplantation of 48.5 years. Median follow-up time was 6.7 years per recipient; total follow-up time, 69 590 person-years. The overall SIRs for SCC, melanoma, and Kaposi sarcoma were 51.9 (95% CI, 48.4-55.5), 2.4 (95% CI, 1.9-3.0), and 54.9 (95% CI, 27.4-98.2), respectively. In those who underwent transplantation in the 1983-1987 period, the unadjusted SIR for SCC was 102.7 (95%, 85.8-122.1), declining to 21.6 (95% CI, 16.8-27.0) in those who underwent transplantation in the 2003-2007 period. Adjusting for different follow-up times and background population risks, as well as age, graft organ, and sex, a decline in the SIR for SCC was found, with SIR peaking in patients who underwent transplantation in the 1983-1987 period and later declining to less than half in patients who underwent transplantation in the 1998-2002, 2003-2007, and 2008-2012 periods, with the relative SIRs being 0.42 (95% CI, 0.32-0.55), 0.31 (95% CI, 0.22-0.42), and 0.44 (95% CI, 0.30-0.66), respectively. CONCLUSIONS AND RELEVANCE: The risk of SCC after organ transplantation has declined significantly since the mid-1980s in Norway. Less aggressive and more individualized immunosuppressive treatment and close clinical follow-up may explain the decline. Still, the risk of SCC in organ transplant recipients remains much higher than in the general population and should be of continuous concern for dermatologists, transplant physicians, and patients.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Rizvi SMH, Aagnes B, Holdaas H, et al. Long-term Change in the Risk of Skin Cancer After Organ Transplantation: A Population-Based Nationwide Cohort Study. JAMA Dermatol. 2017. PMID: 29049612. doi:10.1001/jamadermatol.2017.2984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。